Anticipated Delay in Annual Financial Statements
BioVaxys Technology Corp. (CSE: BIOV) has announced that it might face a short-term delay in the filing of its audited annual financial statements. This delay is a result of challenges faced during the audit process, primarily linked to a recent acquisition involving intellectual property and clinical stage assets.
Details of the Delayed Filing
The Company is required to complete its annual financial filings, which include management's discussion and analysis, as well as CEO and CFO certifications. Under the National Instrument 51-102 regulations, these filings must be submitted by a specified deadline. Unfortunately, due to the acquisition's complexity, BioVaxys is currently unable to meet this deadline of late February.
Factors Behind the Delay
The acquisition of diverse intellectual properties has resulted in an extensive evaluation process. The audit firm, Dale Matheson Carr-Hilton LaBonte LLP (DMCL), has encountered complications while assessing over 120 patents obtained from the previous entity, IMV Inc. The comprehensive review necessitates more time, leading to uncertainty about whether the Required Filings will be made by the stipulated deadline.
Application for Management Cease Trade Order
Given this potential delay, BioVaxys has proactively sought a Management Cease Trade Order (MCTO) from the British Columbia Securities Commission (BCSC). Such an order would restrict trading in the Company's securities by its management until the Required Filings can be completed. This step is taken as a precaution to avoid a more severe “failure-to-file” cease trade order.
Implications of the MCTO
If the BCSC approves the MCTO, the company’s management will be unable to trade shares, but this action will not impact the trading capacity of other shareholders or the Company’s operations. BioVaxys continues to work diligently towards the completion of its annual financial statements, with a target filing date set for March.
Maintaining Communication with Investors
Throughout this period, BioVaxys commits to open communication with its investors. The company plans to provide bi-weekly updates regarding the status of its filings, in accordance with NP 12-203 guidelines. These updates will ensure that stakeholders remain informed during this process.
Company Overview
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies to enhance patient outcomes. Their unique technologies include the DPX immune-educating platform aimed at addressing various diseases. The company's clinical pipelines showcase promising candidates like maveropepimut-S and BVX-0918, tackling significant health challenges such as advanced cancers.
Reassuring Investors
The Company reassures its stakeholders that there are no ongoing insolvency proceedings or undisclosed material issues affecting operations at this time. It emphasizes that all efforts are underway to resolve the audit delays promptly.
Frequently Asked Questions
What is the reason for the delay in filing annual financial statements?
The delay is primarily due to complexities arising from a recent acquisition of numerous patents which requires extensive review and valuation.
What steps is BioVaxys taking in response to the delay?
BioVaxys has applied for a Management Cease Trade Order (MCTO) to prevent management from trading their shares until the filings are completed.
How will the MCTO affect shareholders?
The MCTO will restrict only the management's trading activities; other individuals can still buy or sell shares without impact.
When does BioVaxys expect to complete the Required Filings?
The company is targeting a completion date of March for its Required Filings and will announce when they are submitted.
What is the focus of BioVaxys Technology Corp.?
BioVaxys is dedicated to developing novel immunotherapies with a focus on treating cancers and other significant health issues using unique technological platforms.
